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Abstract: Afghanistan is one of two countries where wild poliovirus (WPV) type 1 remains endemic.
We conducted a facility-based cross-sectional survey of antipoliovirus antibodies in children in
14 provinces of Afghanistan. The provinces were selected based on programmatic priorities for
polio eradication. Children aged 6–11 and 36–48 months attending outpatient clinics were enrolled
in the study. We collected venous blood, isolated serum, and conducted neutralization assays
to detect poliovirus neutralizing antibodies. A total of 2086 children from the 14 provinces were
enrolled. Among the enrolled children, 44.3% were girls; the median age in the 6–11-month group was
9.4 months, and in the 36–48-month group, it was 41.8 months. The most common spoken language
was Pashtu (70.8%). Eighty-two percent of children were fully immunized against all the diseases
in the vaccination schedule of Afghanistan. In the children aged 6–11 months, seroprevalence to
poliovirus type 1 (PV1) was 96.5% and seroprevalence to poliovirus type 3 (PV3) was 93%; in children
aged 36–48 months, seroprevalence to PV1 was 99.5% and to PV3 was 98%. Antipoliovirus antibody
prevalence for poliovirus type 2 (PV2) was 70.5% in the younger group compared with 90.9% in
the older children. Children from Herat and Laghman provinces had almost 100% seroprevalence
to PV1, and other provinces also had high prevalence, ranging from 92.0% to 99.0%. A similar
finding was seen for antibodies against PV3, ranging from 88% to 100% by province. On the contrary,
antibodies to PV2 were low, ranging from 53% for children in the Khost province to around 89%
in Kunduz. There was a cluster of 18 seronegative children in the Nuristan province. Overall, the
polio eradication program of Afghanistan has been successful in achieving high seroprevalence of
poliovirus neutralizing antibodies in the parts of the country included in this study.
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1. Introduction

with regard to jurisdictional claims in

Since the launch of the Global Polio Eradication Initiative in 1988, the number of cases
of paralytic poliomyelitis plummeted by more than 99 percent worldwide by 2000 [1–3].
In 1988, wild poliovirus (WPV) types 1, 2, and 3 were circulating in 125 countries [4,5]. In
2018, only WPV type 1 circulation persisted and was confined to the two endemic countries,
Afghanistan and Pakistan (The last WPV1 case in Nigeria was detected in 2016; interruption
of endemic WPV transmission in the World Health Organization African Region was
certified in August 2020. In 2022, one paralytic WPV1 case was confirmed in Malawi, and
one paralytic WPV1 was detected in Mozambique outside the two endemic countries of
Afghanistan and Pakistan). The WPV type 1 poliovirus detected in Malawi was genetically
linked to a Pakistan sequence detected in 2020 in the province of Sindh [6]. Moreover, the
circulating vaccine-derived poliovirus type 2 (cVDPV2) was also detected recently in the
U.K. in May 2022 and in New York in July 2022 [7]. The current polio epidemiology in
the two endemic countries poses an inimitable challenge for global eradication as these
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countries are being affected by ongoing endemic WPV1 and cVDPV2 transmission. Between
January 2020 to November 2022, Afghanistan reported 60 cases of WPV1 and 351 cases of
cVDPV2 [8].
In Afghanistan, armed conflict and insecurity, coupled with frequent population
movements, have impeded access by children to vaccinations [9]. Despite this, national
routine vaccination coverage rates have increased from 35% in 2001 to 66% in 2011 [10],
as estimated by the WHO/UNICEF. The most recent available survey results from the
Afghanistan Health Survey 2018 (AHS) estimate the national immunization coverage at
50% among children aged 12–23 months [11] in the country. The routine immunization
schedule in Afghanistan includes oral poliovirus vaccine (OPV) given at birth; 6, 10, and
14 weeks of age; and inactivated poliovirus vaccine (IPV), introduced in 2016 into the
routine immunization schedule, administered at 14 weeks of age [12], as presented in
Table 1 below.
Table 1. Childhood vaccination schedule Afghanistan.
S. No.

Age

Vaccines

1
2
3
4
5
6
7

Birth (0–11 months)
Birth (as soon as possible within 14 days of life)
6 Weeks
10 Weeks
14 Weeks
9 Months
18 Months

BCG
OPV0
Pentavalent 1, OPV1
Pentavalent 2, OPV2
Pentavalent 3, OPV3
Measles, OPV4
Measles

The estimated routine immunization coverage proportion for the third OPV dose by
age 11 months was 60% in 2015–2017; for IPV, it was 65% in 2017 [13]. In April 2016, a
globally synchronized switch from trivalent OPV (tOPV; types 1, 2, and 3 Sabin strains) to
bivalent OPV (bOPV; types 1 and 3 Sabin strains) [14] resulted in the cessation of use of
Sabin OPV type 2 strain in Afghanistan in routine immunization.
Afghanistan’s polio National Eradication Action Plan serves as a guide for all polio
eradication activities, and since its first adoption during 2012–2013, there has been a
significant reduction in the geographic spread of the virus through the consistent and welltracked implementation of immunization campaigns [15]. In 2016, Emergency Operation
Centers (EOCs) were established at the national and regional levels to strengthen and
coordinate the efforts of all partners involved. Four National Immunization Days (NIDs)
targeting 10 million children and six subnational NIDs targeting six million children were
conducted in 2017, along with three mop-up campaigns [16]. In 2018, a total of three NIDs
and six subnational NIDs were conducted. According to the World Health Organization’s
independent postcampaign monitoring data from the Afghanistan office, coverage in each
campaign during 2017 was more than 94%. The number of inaccessible children declined
from 391,000 in 2017 to 138,000 in March 2018 but drastically increased in May 2018 when
996,326 children were reported inaccessible due to vaccination bans, mostly in the southern
region. A special vaccination strategy was adopted in 2017 to reach seasonal nomadic
populations in the southeastern region. Children on the move, especially those returning
from Pakistan and Iran, were immunized by crossborder teams (CBTs) and permanent
transit teams (PTTs) using OPV and IPV [17]. Five provinces in Afghanistan were identified
as high-risk for sustaining poliovirus transmission based on poliovirus epidemiology,
access to supplementary immunization activities (SIAs), estimated population immunity,
and the presence of refugees and internally displaced persons (IDPs). These provinces
are Kandahar, Helmand, Nangarhar, Kunar, and Farah [18]. In 2017, when this study was
being planned, there were 14 cases of WPV1 reported, and 21 cases were reported in 2018
across Afghanistan, with most cases in 2017 and 2018 in the high-risk provinces in the
eastern and southern regions of the country. Moreover, the WPV1 cases in the country
are constantly rising. Between January 2020 to November 2021, 60 WPV1 cases were
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reported in Afghanistan, with most cases clustered in the eastern and southern regions of
the country [8].
Serological surveys of antipoliovirus neutralizing antibodies have been carried out in
many countries as a tool to evaluate program performance, assess population immunity
gaps, and identify areas of high risk for poliovirus transmission [19–22]. The poliovirus
immunity profiles of young children in China, Egypt, Indonesia, Madagascar, and India [23] have provided country-specific results that have led to programmatic actions and
an immunity benchmark for the eradication initiative. Similar studies were previously
conducted in Afghanistan to assess the seroprevalence among children under five years
of age. In 2013, a study assessed poliovirus immunity among children under five years
in the accessible areas of Afghanistan [24]; in 2017, a facility-based study focusing on
children aged 6–11 and 36–48 months in polio high-risk areas in Kandahar Province [25]
was carried out. These studies helped to analyze the trend of seroprevalence among the
target population in the country. Providing scientific evidence about the existing level
of seroprevalence, vaccination coverage, and its effectiveness in Afghanistan will help in
designing informed decisions to address the existing challenges in poliovirus eradication
efforts, enabling national and international stakeholders to devise measures to further
improve the quality and effectiveness of both routine and supplementary immunizations
activities and to help evaluate the risk of future outbreaks of WPV1 and cVDPV2 in the
country.
Considering the importance of quantifying the levels of serological protection against
poliovirus, we conducted an antipoliovirus neutralizing antibody serological survey among
children who were visiting selected health facilities in 14 provinces of Afghanistan. The
provinces selected were high risk for polio or in proximity to those areas with potential
immunity gap concerns.
2. Materials and Methods
2.1. Study Design and Study Population
A facility-based cross-sectional survey was conducted in 14 polio program priority
provinces of Afghanistan. The provinces were selected based on programmatic priority
for polio, chronic accessibility challenges, poor campaign quality, presence of special
populations (refugees, returnees, and nomads), proximity to the border with Pakistan,
and concerns about program quality (Figure 1). A central health facility in the province
was selected as the study site (Table 2). The choice of regional and provincial hospitals
in the selected provinces was based on reported referral patterns to provide a reasonable
representation of the catchment population.
Table 2. Health facilities in targeted provinces.
Health Facility

6–11 Months

36–48 Months

Total

Balkh Regional Hospital, BULKH
Herat Regional Hospital, FARAH
Ghanzi Provincial Hospital, GHAZNI
Herat Regional Hospital, HERAT
Indira Ghandi Hospital and Kochi
(Nomad) Hospital, KABUL
Khost Provincial Hospital, KHOST
Nangarhar Regional Hospital, KUNAR
Kunduz Regional Hospital, KUNDUZ
Nangarhar Regional Hospital, LAGHMAN
Nangarhar Regional Hospital, NANGARHAR
Nangarhar Regional Hospital, NORISTAN
Paktika Provincial Hospital, PAKTIKA
Paktya Provincial Hospital, PAKITA
Bost Hospital Lashkargah, HELMAND

81 (7.6%)
75 (7.1%)
72 (6.8%)
67 (6.3%)

64 (6.2%)
79 (7.7%)
72 (7.0%)
72 (7.0%)

145 (6.9%)
154 (7.4%)
144 (6.9%)
139 (6.7%)

76 (7.2%)

79 (7.7%)

155 (7.4%)

75 (7.1%)
75 (7.1%)
75 (7.1%)
77 (7.3%)
71 (6.7%)
74 (7.0%)
85 (8.0%)
73 (6.9%)
83 (7.8%)

75 (7.3%)
75 (7.3%)
74 (7.2%)
75 (7.3%)
79 (7.7%)
78 (7.6%)
65 (6.3%)
72 (7.0%)
70 (6.8%)

150 (7.2%)
150 (7.2%)
149 (7.1%)
152 (7.3%)
150 (7.2%)
152 (7.3%)
150 (7.2%)
145 (6.9%)
153 (7.3%)
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in targeted
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caretaker at the selected health facilities were approached for participation in the study. A
Health
Facility was used for the selection
6−11 Months
36−48 from
Months
Total
purposive sampling
technique
of children
both age
groups
Balkh
Regional
Hospital,
BULKH
81
(7.6%)
64
(6.2%)
145
(6.9%)to
at each health facility. Children attending a selected health facility for ailments unrelated
Herat
Regional Hospital,
FARAHadult caregiver
75 (7.1%)
79for
(7.7%)
154 (7.4%)
polio and
accompanied
by a primary
were eligible
enrollment.
Before
Ghanzi Provincial Hospital, GHAZNI
72 (6.8%)
72 (7.0%)
144 (6.9%)
enrollment in the study, a detailed history was taken, and a physical examination
was
Herat Regional Hospital, HERAT
67 (6.3%)
72 (7.0%)
139 (6.7%)
performed on each child to ascertain eligibility. Exclusion criteria encompassed severe acute
Indira Ghandi Hospital and Kochi
or chronic illness requiring immediate medical attention,
including79immunodeficiency
and
76 (7.2%)
(7.7%)
155 (7.4%)
(Nomad) Hospital, KABUL
neoplasms.
Khost Provincial Hospital, KHOST
75 (7.1%)
75 (7.3%)
150 (7.2%)
Informed consent was obtained from caretakers of all eligible children enrolled in this
Nangarhar Regional Hospital, KUNAR
75 (7.1%)
75 (7.3%)
150 (7.2%)
study. In case of refusal to participate, parents and caregivers were asked to answer a few
Kunduz Regional Hospital, KUNDUZ
75 (7.1%)
74 (7.2%)
149 (7.1%)
questions
(e.g., age of child; district and village of residence;
population
group, e.g.,
nomad,
Nangarhar Regional Hospital, LAGHMAN
77 (7.3%)
75 (7.3%)
152 (7.3%)
returnee,
refugee,
etc.;
travel
history;
and
OPV
and
IPV
immunization
status
of
the
child
Nangarhar Regional Hospital, NANGARHAR
71 (6.7%)
79 (7.7%)
150 (7.2%)
(routine
immunization
(RI)
and
SIAs).
These
data
were
collected
to
assist
in
quantifying
Nangarhar Regional Hospital, NORISTAN
74 (7.0%)
78 (7.6%)
152 (7.3%)
the possible
effects of Hospital,
the nonresponse
serosurvey 65
results.
and
Paktika Provincial
PAKTIKArate on the
85 (8.0%)
(6.3%) Enrolment
150 (7.2%)
samplePaktya
collection
were
performed
during
25
October–20
November
2017.
For
provincial
Provincial Hospital, PAKITA
73 (6.9%)
72 (7.0%)
145 (6.9%)
level Bost
estimates,
the
required HELMAND
sample size in each83age
group was
calculated153
assuming
Hospital
Lashkargah,
(7.8%)
70 (6.8%)
(7.3%)
seroprevalence of 90%, precision of ±6%, and alpha = 0.05. A sample size of 140 children
in each
province
(706−11
in each
group)
was
calculated
enrolledclinics
in thewith
survey
after
Children
aged
and age
36−48
months
attending
theand
outpatient
an adult
obtaining
the
consent
of
a
parent
or
primary
caregiver.
caretaker at the selected health facilities were approached for participation in the study.

A purposive sampling technique was used for the selection of children from both age
groups at each health facility. Children attending a selected health facility for ailments
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2.2. Training of the Field Team
Training of locally hired field teams was conducted over three days in Kabul. The field
team was specially trained to collect data using the structured questionnaire on handheld
devices, and phlebotomists were trained in phlebotomy procedures, and sample labelling,
handling, and transportation. For conceptual clarity of the survey, team field pilot testing
was conducted in the Indira Gandhi Hospital in Kabul. All steps of the survey were
followed in the pilot exercise, including the data collection, phlebotomy, sample handling
and transportation, and cold chain guidelines.
2.3. Data Collection
A structured questionnaire was developed to collect data on demography, socioeconomic status (SES), comorbidities, nutritional status, and vaccination history. Vaccination
history for OPV and IPV received through routine immunization was assessed from vaccination cards when available or by parental/caregiver recall if cards were not available.
The number of OPV or IPV doses received through campaigns was always obtained by
parental/caregiver recall, as no documentation exists.
Data at the facility were electronically collected using handheld devices running Android Operating System. Android Version 5.1.1 created by Google, 1600 Amphitheatre
Parkway Mountain View, CA 94043, USA was used. A customized data collection application was developed in-house using Java language with MySQL, and SQLite was running at
the backend for data storage. The application offered built-in features for real-time data
quality checking and identification of missing information, inconsistencies, outliers, and
other possible errors and omissions. The users were prompted for any such errors at the
time of data collection to ensure quality data.
2.4. Laboratory Methodology
Trained phlebotomists collected 2 mL of peripheral blood from each subject using
standard venipuncture techniques. After clotting and centrifugation, sera were separated,
transferred into labeled sterile cryovials, immediately stored in a cold box with ice packs,
and transported to the nearest provincial or regional hospital for temporary storage in
the expanded program on immunization (EPI) cold chain. After completion of field activities, samples were transferred under reverse cold chain conditions to Kabul for further
transportation to the Aga Khan University (AKU) for further transportation to the AKU
Nutrition Research Laboratory in Karachi. In the laboratory, two aliquots were prepared,
one for backup and one for transport to the Centers for Disease Control and Prevention in
Atlanta, USA, for poliovirus neutralization assay testing [15]. Seroprevalence, defined as
the proportion of subjects with titers ≥3 [1/dil], was calculated for each poliovirus serotype
(PV1, PV2, and PV3).
2.5. Statistical Analysis
Frequencies and percentages were calculated for categorical variables to describe the
characteristics of the participants. Seroprevalence estimates by PV type were calculated as
proportions with their 95% confidence intervals. All analyses were completed using Stata
Version 12 [26], sourced from StataCorp LLC, College Station, TX, USA.
2.6. Ethical Review
This study received approval from the Ethical Review Committees of the World
Health Organization, Aga Khan University, and the National Bioethics Committee of
the Government of Pakistan and from the Institutional Review Board of the Ministry of
Public Health, Afghanistan. The Center for Global Health, Centers for Disease Control and
Prevention Office of Human Subjects Research Protection, deemed this study as nonresearch
and deferred approval to the Institutional Review Board of Aga Khan University (CDC
project ID 0900f3eb819a146a).
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3. Results
Blood samples were obtained from 2086 (99%) eligible children from both age cohorts
out of 2104 children who were approached to participate in the study. There were 44.3%
girls among the enrolled children (44% in the age group of 6–11 months and 44.5% in the
age group of 36–48 months); the median age in the 6–11 months group was 9.4 months
and that in the 36–48 months group was 41.8 months. Table 3 shows the demographic
indicators, sex, and vaccination history of the study population. The respondents could
report more than one spoken language; the most common was Pashtu (70.8%), followed
by Dari (30.5%). Around 82% of children were fully immunized against all the diseases in
the vaccination schedule of Afghanistan: 92% in the older age group and 72% younger age
group.
Table 3. Baseline characteristics of the study population.
Indicators
Interview Status
Completed
Incomplete
Refused
Blood sample collected
Language
Pashtu
Dari
Nuristani
Female
Child Age (months)
Immunization status
Not immunized
Partially immunized
Fully immunized
Received IPV
Received OPV at checkpoint while traveling
Live in current residence for 12 months of year

6–11 Months

36–48 Months

Total

n = 1068

n = 1036

n = 2104

1059 (99.2%)
7 (0.7%)
2 (0.2%)
1058 (99.9%)

1029 (99.3%)
5 (0.5%)
2 (0.2%)
1028 (99.9%)

2088 (99.2%)
12 (0.6%)
4 (0.2%)
2086 (99.9%)

767 (72.4%)
310 (29.3%)
69 (6.5%)
466 (44.0%)
9.4 (1.7)

712 (69.2%)
327 (31.8%)
68 (6.6%)
458 (44.5%)
41.8 (4.8)

1479 (70.8%)
637 (30.5%)
137 (6.6%)
924 (44.3%)
25.4 (16.6)

25 (2.4%)
276 (26.1%)
758 (71.6%)
836 (78.9%)
576 (54.4%)
1052 (99.3%)

19 (1.8%)
66 (6.4%)
944 (91.7%)
761 (74.0%)
596 (57.9%)
1025 (99.6%)

44 (2.1%)
342 (16.4%)
1702 (81.5%)
1597 (76.5%)
1172 (56.1%)
2077 (99.5%)

In children aged 6–11 months, seroprevalence to poliovirus type 1 (PV1) was 96.5%,
and seroprevalence to poliovirus type 3 (PV3) was 93.0%; in children aged 36–48 months,
seroprevalence to PV1 was 99.5% and that to PV3 was 98.1% (Figure 2). Antipoliovirus
neutralizing antibody prevalence levels for poliovirus type 2 (PV2) were much lower among
the study population: 70.5% in younger compared with 90.9% in older children.
Children from Herat and Laghman provinces had almost 100% seroprevalence to
PV1, whereas children from other provinces also had high prevalence, 92–99% (Figure 3).
High seroprevalence was similarly observed against PV3, 88–100%. Neutralizing antibody
prevalence levels to PV2 were lower, ranging from 53% for Khost province to 89.9% for
Kunduz. There was a cluster of 18 children who were seronegative to PV1 or PV3 in Poruns
district, Nuristan province.

among
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4.4. Discussion
Discussion
This survey provides critical information on the immunity status of children against
poliovirus in high-risk provinces of Afghanistan. The seroprevalence of antipoliovirus
neutralizing antibodies was >95% for both age groups for PV1 and for PV3 in the older age
Figure 3.
Seroprevalence
by poliovirus
serotypeantibodies
and province
of residence,
Afghanistan,
2017.
group.
The
PV3 antipoliovirus
neutralizing
level
among the
younger age
group
was 93%. Neutralizing antibody prevalence to PV2 was ~20% lower among children aged
4. Discussion
6–11
months compared with those aged 36–48 months.
The lower PV2 seroprevalence among the younger study population is explained
by the inclusion of children in the younger age group who were born after the switch
from tOPV to bOPV. Children born before the switch should not have received any type 2
OPV, but they had all received one IPV dose at 14 weeks of age or after. Former studies
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on immunogenicity of one dose of IPV administered at 14 weeks and bOPV at 6, 10, and
14 weeks showed a type 2 seroconversion rate of 69–80% [27]. In this study, older Afghan
children born after the switch had a PV2 seroconversion rate of 70.5%. Circulating vaccinederived polioviruses (cVDPVs) can emerge in settings with low population immunity
and cause paralysis. Type-2-naïve children who were born after the switch from tOPV
to bOPV and who lived in areas with chronically low routine and supplementary polio
immunization coverage are at particularly high risk of cVDPV2 infection.
The findings of this study are consistent with the results of a seroprevalence survey
conducted in Kandhar province in 2017 [25], which recorded a high seroprevalence for PV1
and PV3 among children of both age groups (6–11 months and 36–48 months) and a low
seroprevalence for PV2 among the younger age cohort compared with the older children. A
similar study in polio high-risk areas of Pakistan in 2016 recorded high seroprevalence for
PV1 and PV3 and low for PV2 among younger children [28]. Another study conducted in
Pakistan in 2016 to quantify immunity and field efficacy of type-2-containing polio vaccines
after cessation of the trivalent oral polio vaccine revealed that type 2 seroprevalence was
50% among children 6–11 months old born after the withdrawal of tOPV within April
2016 [29]. Similar findings were recorded in a study that assessed population immunity in
a persistently high-risk area for wild poliovirus transmission in Western Uttar Pradesh of
India in 2007 [30]. Nevertheless, pockets of underimmunized children remain in high-risk
areas, which may continue to transmit WPV within the two neighboring countries. In this
survey, we identified a cluster of seronegative children in the district Poruns of Nuristan
province. Similar clusters may exist elsewhere. In a previous study conducted in 2013 to
assess the polio virus immunity among children under five years of age in Afghanistan, a
cluster of 14 seronegative children was reported in the country, with the majority in the
Paktika Province, in the southern region [29]. To eradicate poliovirus from the country,
it is imperative that the polio program reaches children who are chronically missed by
vaccination campaigns due to their residence in hard-to-reach areas as well as those who
are constantly migrating and fail to receive routine or campaign immunization services.
In addition, the immunization program needs further strengthening to provide routine
immunization against all three poliovirus types to all children, including in high-risk
locations. As the immunization program strengthens, parent-held vaccination cards need
to be systematically provided by the immunization program [16].
Children remaining inaccessible for vaccination remains a challenge in stopping the
transmission of WPV. A significant number of children in the hard-to-reach and securitycompromised areas in the country are being missed from vaccination during SIAs. The
national polio eradication program of Afghanistan classifies the districts in the country into
four categories as per their access status: category one being fully accessible, two—partially
accessible, three—accessible with limitations, and four—fully inaccessible [15]. Although
the number of inaccessible children varies from campaign to campaign, over the past two
years (2105), access deteriorated, particularly in the eastern and northeastern regions [15].
This study has some limitations. The survey population may not be representative of
the entire population of Afghanistan or be generalizable to the greater district or province
as we conducted a facility-based survey that might have resulted in an overestimation of
seroprevalence of antibody against poliovirus because children who are not reached by
immunization activities may be less likely to be taken to health care facilities. Furthermore, there is an issue of potential recall bias in caretaker-reported immunization data.
Notwithstanding these limitations, our findings are that the polio eradication program of
Afghanistan has been successful in achieving overall high seroprevalence of poliovirus neutralizing antibodies in the parts of the country included in this study, which was conducted
in 2017.
5. Conclusions
Because the findings of this study reflect that there exists a high proportion of seroprevalence of poliovirus neutralizing antibodies among the children of both age cohorts
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enrolled in this study, which is indicative of the effectiveness of the polio eradication program in Afghanistan toward achieving its underline goal in making the country polio-free.
However, there is low PV2 seroprevalence among the younger age group, as found in this
study. In addition, this study identified a cluster of seronegative children in the district
Poruns of Nuristan province. Furthermore, there is also an accessibility issue in reaching the
children in security-compromised areas and districts with always-low routine immunization coverage. Coupled with this, there is high population mobility in the country. These
factors increase the risk of cVDPV2 infection among the younger type-2-naive children
who live in these inaccessible yet low-immunization-coverage areas and districts and are
part of the mobile population. To further enhance immunization coverage in inaccessible
areas, there is a need to focus on developing context-specific strategies to mobilize and
sensitize the community to the acceptance of vaccination.
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